Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and in vivo evaluation
Source abstract
Abstract
TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) gene therapy is considered as one of the promising approaches for cancer treatment. Polyamidoamine (PAMAM) is one of the most extensively applied polymeric vector in gene delivery. In the current study, PAMAM (G4 and G5) dendrimers were modified with alkyl-carboxylate chain, PEG and cholesteryl chloroformate in order to enhance transfection efficiency through overcoming extracellular and intracellular barriers while reducing PAMAM cytotoxicity. Gene delivery efficiency of synthetized vectors was evaluated by both GFP (green fluorescent protein) reporter gene and TRAIL plasmid in colon cancer cells, in vitro and in vivo. The obtained results demonstrated that PAMAM G4-alkyl-PEG (3%)-Chol (5%)-TRAIL complexes at C/P ratio 4 could significantly increase cell death (29.45%) in comparison with unmodified PAMAM vector (15.5%). Moreover, in vivo study in C26 tumor-bearing BALB/c mice suggested that the prepared non-toxic safe vector could inhibit the tumor growth. This study represented the potent vehicle based on cholesterol-grafted PAMAM dendrimers with alkyl-PEG modification for efficient gene delivery in vitro and in vivo.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmacutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences
Department of Molecular Pathology and Cytogenetics, Mashhad University of Medical Sciences, Imam Reza Hospital
Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences
References (42)
Show source-provided references
1. 10.1039/C7NR01469D10.1039/C7NR01469D ↗
2. 10.3390/antib604001610.3390/antib6040016 ↗
3. 10.1016/j.canlet.2011.10.01010.1016/j.canlet.2011.10.010 ↗
4. 10.1039/C7NR04959E10.1039/C7NR04959E ↗
5. 10.3332/ecancer.2016.66010.3332/ecancer.2016.660 ↗
6. 10.1517/14712598.2016.116926910.1517/14712598.2016.1169269 ↗
7. 10.1016/j.tips.2014.09.00810.1016/j.tips.2014.09.008 ↗
8. 10.1007/s12010-015-1723-y10.1007/s12010-015-1723-y ↗
9. 10.1016/j.ijpharm.2017.01.04410.1016/j.ijpharm.2017.01.044 ↗
10. 10.1016/j.mattod.2015.06.00310.1016/j.mattod.2015.06.003 ↗
11. 10.1016/j.polymer.2014.12.05110.1016/j.polymer.2014.12.051 ↗
12. 10.1080/01480545.2016.124531810.1080/01480545.2016.1245318 ↗
13. 10.1177/088532821455101010.1177/0885328214551010 ↗
14. 10.1016/j.ijpharm.2016.05.02110.1016/j.ijpharm.2016.05.021 ↗
15. Jang H-S, Lee Y, Kim T-I, et al. Synthesis, characterization and application of dendritic lipids for gene delivery. Notes. 2012;33:1353.
16. 10.1021/mp500572v10.1021/mp500572v ↗
17. 10.1016/j.jconrel.2010.01.03410.1016/j.jconrel.2010.01.034 ↗
18. 10.1016/j.colsurfa.2007.04.10910.1016/j.colsurfa.2007.04.109 ↗
19. 10.1002/jgm.272610.1002/jgm.2726 ↗
20. 10.1016/j.ijpharm.2012.08.04310.1016/j.ijpharm.2012.08.043 ↗
21. 10.1177/088532821559966710.1177/0885328215599667 ↗
22. Mahato RI Han SO Furgeson DY.Cationic lipopolymer as biocompatible gene delivery agent. 2004;US Patent# 6 696 038.
23. 10.1007/s11051-016-3413-210.1007/s11051-016-3413-2 ↗
24. 10.1080/21691401.2016.123680510.1080/21691401.2016.1236805 ↗
25. Langroodi FA, Ghahestani ZH, Alibolandi M, et al. Evaluation of the effect of crocetin on antitumor activity of doxorubicin encapsulated in PLGA nanoparticles. Nanomed J. 2016;3:23–34.
26. 10.1021/mp300602j10.1021/mp300602j ↗
27. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
28. 10.2147/DDDT.S9584310.2147/DDDT.S95843 ↗
29. 10.1016/j.biomaterials.2011.01.05410.1016/j.biomaterials.2011.01.054 ↗
30. 10.1073/pnas.03054509710.1073/pnas.030545097 ↗
31. Wu GS, Burns TF, Zhan Y, et al. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999;59:2770–2775.
32. 10.1039/C7PY00882A10.1039/C7PY00882A ↗
33. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
34. 10.1073/pnas.060770510310.1073/pnas.0607705103 ↗
35. 10.1021/acs.molpharmaceut.5b0094610.1021/acs.molpharmaceut.5b00946 ↗
36. 10.1016/j.actbio.2016.07.01510.1016/j.actbio.2016.07.015 ↗
37. 10.1016/j.ijpharm.2010.04.02710.1016/j.ijpharm.2010.04.027 ↗
38. 10.1016/j.biocel.2017.10.00510.1016/j.biocel.2017.10.005 ↗
39. 10.1016/j.colsurfb.2013.12.03910.1016/j.colsurfb.2013.12.039 ↗
40. 10.1016/j.bmcl.2016.04.00710.1016/j.bmcl.2016.04.007 ↗
41. 10.1590/s2175-9790201700030014010.1590/s2175-97902017000300140 ↗
42. 10.1016/j.nano.2017.05.01110.1016/j.nano.2017.05.011 ↗